drugset / Trial / NCT06071156

Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis

NCT06071156

RandomizedParallel-groupOpen-labelPrevention

Summary

To determine the utility of serial cardiac magnetic resonance (CMR) imaging for guidance of therapy management in patients treated with anakinra due to recurrent pericarditis (RP), compared with c-reactive protein (CRP) assay alone.

Timeline

Start
2018-01-01
Primary completion
2022-05-05
Completion
2025-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anakinra Protein / enzyme biologic 2 mg/kg
Comparator Anakinra Protein / enzyme biologic 100 mg

Indications